FHIT

FHIT
Available structures
PDBOrtholog search: PDBe RCSB
Identifiers
Aliases FHIT, AP3Aase, FRA3B, fragile histidine triad
External IDs MGI: 1277947 HomoloGene: 21661 GeneCards: FHIT
Genetically Related Diseases
myopia, orofacial cleft, Asperger syndrome, attention deficit hyperactivity disorder[1]
RNA expression pattern
More reference expression data
Orthologs
Species Human Mouse
Entrez

2272

14198

Ensembl

ENSG00000189283

ENSMUSG00000060579

UniProt

P49789

O89106

RefSeq (mRNA)

NM_001166243
NM_002012
NM_001320899
NM_001320900
NM_001320901

NM_010210
NM_001308285
NM_001308286

RefSeq (protein)

NP_001159715.1
NP_002003.1
NP_001307828.1
NP_001307829.1

NP_001295215.1
NP_034340.1

Location (UCSC) Chr 3: 59.75 – 61.25 Mb Chr 14: 9.55 – 11.16 Mb
PubMed search [2] [3]
Wikidata
View/Edit HumanView/Edit Mouse

Bis(5'-adenosyl)-triphosphatase also known as fragile histidine triad protein (FHIT) is an enzyme that in humans is encoded by the FHIT gene.[4][5]

Function

FHIT is also known as human accelerated region 10. It may, therefore, have played a key role in differentiating humans from apes.[6]

This gene, a member of the histidine triad gene family, encodes a diadenosine P1,P3-bis(5'-adenosyl)-triphosphate adenylohydrolase involved in purine metabolism. The gene encompasses the common fragile site FRA3B on chromosome 3, where carcinogen-induced damage can lead to translocations and aberrant transcripts of this gene. In fact, aberrant transcripts from this gene have been found in about half of all esophageal, stomach, and colon carcinomas.[7]

Though the exact molecular function of FHIT is still partially unclear, the gene works as a tumor suppressor as it has been demonstrated in animal studies.[8][9][10] Furthermore FHIT has been shown to synergize with VHL, another tumor suppressor, in protecting against chemically - induced lung cancer.[11]

FHIT also acts as a tumor suppressor of HER2/neu driven breast cancer.[12]

Interactions

FHIT has been shown to interact with UBE2I.[13]

References

  1. "Diseases that are genetically associated with FHIT view/edit references on wikidata".
  2. "Human PubMed Reference:".
  3. "Mouse PubMed Reference:".
  4. Ohta M, Inoue H, Cotticelli MG, Kastury K, Baffa R, Palazzo J, Siprashvili Z, Mori M, McCue P, Druck T, Croce CM, Huebner K (Apr 1996). "The FHIT gene, spanning the chromosome 3p14.2 fragile site and renal carcinoma-associated t(3;8) breakpoint, is abnormal in digestive tract cancers". Cell. 84 (4): 587–97. doi:10.1016/S0092-8674(00)81034-X. PMID 8598045.
  5. Pekarsky Y, Campiglio M, Siprashvili Z, Druck T, Sedkov Y, Tillib S, Draganescu A, Wermuth P, Rothman JH, Huebner K, Buchberg AM, Mazo A, Brenner C, Croce CM (Aug 1998). "Nitrilase and Fhit homologs are encoded as fusion proteins in Drosophila melanogaster and Caenorhabditis elegans". Proc. Natl. Acad. Sci. U.S.A. 95 (15): 8744–9. doi:10.1073/pnas.95.15.8744. PMC 21147Freely accessible. PMID 9671749.
  6. Pollard KS, Salama SR, Lambert N, Lambot MA, Coppens S, Pedersen JS, Katzman S, King B, Onodera C, Siepel A, Kern AD, Dehay C, Igel H, Ares M, Vanderhaeghen P, Haussler D (2006-08-16). "An RNA gene expressed during cortical development evolved rapidly in humans". Nature. 443 (7108): 167–72. doi:10.1038/nature05113. PMID 16915236. supplement
  7. "Entrez Gene: FHIT fragile histidine triad gene".
  8. Fong LY, Fidanza V, Zanesi N, Lock LF, Siracusa LD, Mancini R, Siprashvili Z, Ottey M, Martin SE, Druck T, McCue PA, Croce CM, Huebner K (April 2000). "Muir-Torre-like syndrome in Fhit-deficient mice". Proc. Natl. Acad. Sci. U.S.A. 97 (9): 4742–7. doi:10.1073/pnas.080063497. PMC 18303Freely accessible. PMID 10758156.
  9. Zanesi N, Fidanza V, Fong LY, Mancini R, Druck T, Valtieri M, Rüdiger T, McCue PA, Croce CM, Huebner K (August 2001). "The tumor spectrum in FHIT-deficient mice". Proc. Natl. Acad. Sci. U.S.A. 98 (18): 10250–5. doi:10.1073/pnas.191345898. PMC 56947Freely accessible. PMID 11517343.
  10. Zanesi N, Pekarsky Y, Croce CM (December 2005). "A mouse model of the fragile gene FHIT: From carcinogenesis to gene therapy and cancer prevention". Mutat. Res. 591 (1-2): 103–9. doi:10.1016/j.mrfmmm.2005.05.016. PMID 16085127.
  11. Zanesi N, Mancini R, Sevignani C, Vecchione A, Kaou M, Valtieri M, Calin GA, Pekarsky Y, Gnarra JR, Croce CM, Huebner K (August 2005). "Lung cancer susceptibility in Fhit-deficient mice is increased by Vhl haploinsufficiency". Cancer Res. 65 (15): 6576–82. doi:10.1158/0008-5472.CAN-05-1128. PMID 16061637.
  12. Bianchi F, Tagliabue E, Ménard S, Campiglio M (March 2007). "Fhit expression protects against HER2-driven breast tumor development: unraveling the molecular interconnections". Cell Cycle. 6 (6): 643–6. doi:10.4161/cc.6.6.4033. PMID 17374991.
  13. Shi Y, Zou M, Farid NR, Paterson MC (December 2000). "Association of FHIT (fragile histidine triad), a candidate tumour suppressor gene, with the ubiquitin-conjugating enzyme hUBC9". Biochem. J. 352 Pt 2 (2): 443–8. doi:10.1042/0264-6021:3520443. PMC 1221476Freely accessible. PMID 11085938.


This article is issued from Wikipedia - version of the 5/20/2016. The text is available under the Creative Commons Attribution/Share Alike but additional terms may apply for the media files.